Shares of Evotec SE (NASDAQ:EVO - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $2.84 and last traded at $2.97, with a volume of 106057 shares trading hands. The stock had previously closed at $3.06.
Evotec Stock Performance
The business has a fifty day simple moving average of $3.81 and a 200 day simple moving average of $4.07. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Investors Weigh In On Evotec
A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new position in Evotec during the fourth quarter worth about $27,000. CSS LLC IL acquired a new position in shares of Evotec during the 4th quarter valued at about $50,000. Bank of America Corp DE lifted its holdings in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after acquiring an additional 9,289 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec in the fourth quarter worth approximately $166,000. Finally, DCF Advisers LLC grew its holdings in Evotec by 5.9% in the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after purchasing an additional 12,816 shares during the period. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
